Skip to main content
Premium Trial:

Request an Annual Quote

SoluLink Pockets $300K in VC Cash to Continue Marketing Its Biomolecule Conjugation Technology

NEW YORK (GenomeWeb News) — Bioconjugation product developer SoluLink today reported it has received $300,000 in venture capital from Plymouth Venture Partners.
SoluLink President Steve DeGraw said the investment will enable the company to continue marketing existing products, and to integrate them into new markets.
DeGraw also said the company is planning a public rollout of its products this fall in the form of a catalog and trade show appearances, and hopes to secure more financing in the near future.
This is Plymouth’s first funding agreement with San Diego-based SoluLink.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.